Avancerad sökning
Visar resultat 1 - 5 av 18 avhandlingar som matchar ovanstående sökkriterier.
1. Mast cells: bad enemies or good friends? : A study of the effects of IgG immune complexes on mast cell biology
Sammanfattning : Mast cells are classically defined as bad enemies to human health due to their critical involvement in IgE-dependent allergy by virtue of the expression of the high affinity IgE receptor, FcgammaRI, on these cells. However, mouse mast cells also express FcgammaRIIB and FcgammaRIIIA, two receptors that bind IgG especially in the form of IgG immune complexes. LÄS MER
2. Studies on streptococcal M proteins. Interactions with IgA and human complement regulators
Sammanfattning : The human pathogenic bacterium Streptococcus pyogenes (group A Streptococcus) expresses several different virulence factors. Of these, the M protein is regarded as one of the most important, because it confers resistance to phagocytosis, allowing the bacterium to multiply in blood. LÄS MER
3. Human adipose tissue. Genes predominantly expressed in the visceral depot and in hypertrophic adipocytes
Sammanfattning : The obesity prevalence is increasing worldwide and obesity is closely linked to type 2 diabetes and cardiovascular disease. Both visceral fat accumulation and enlarged adipocyte size are risk factors for obesity related metabolic disorders. LÄS MER
4. Immunoglobulin-Fc receptor interactions in cytotoxicity and phagocytosis mediated by lymphocytes and monocytes
Sammanfattning : Antibody dependent cellular cytotoxicity (ADCC) and phagocytosis mediated by lymphocytes and monocytes depend on IgG-binding Fc receptors on the effector cells. Properties of the immunoglobulin-Fc receptor interactions of human lymphocytes and monocytes were investigated using 51Cr release assays for detection of cytolysis or phagocytosis of target erythrocytes. LÄS MER
5. Rational and Combinatorial Engineering of Affinity Proteins Towards Therapeutical Applications
Sammanfattning : Protein engineering has had an immense impact on the development of biological drugs, including replacement therapies with engineered versions of insulin or factor VIII to treat diabetes or bleeding disorders, and monoclonal antibodies to treat cancer and various other malignancies. Now, with the next generation of treatment modalities coming up, including monoclonal reagents based on alternative scaffolds, gene and cell therapies, the importance of protein engineering to tailor-make these treatments is likely to increase further. LÄS MER